Kaasch, Achim J. and Seifert, Harald (2016). Oritavancin: a long-acting antibacterial lipoglycopeptide. Future Microbiol., 11 (7). S. 843 - 856. LONDON: FUTURE MEDICINE LTD. ISSN 1746-0921

Full text not available from this repository.

Abstract

Oritavancin is a new lipoglycopeptide antibacterial agent with an exceptionally long terminal half-life and a rapid bactericidal effect. Multiple mechanisms of action lead to a broad activity against Gram-positive bacteria, such as staphylococci, streptococci and enterococci, including methicillin-resistant Staphylococcus aureus. Its long terminal half-life allows for single-dose treatment of acute bacterial skin and skin structure infections. Oritavancin was found to be safe and effective in treating acute bacterial skin and skin structure infections in adults and it is currently approved in the USA and in Europe for this indication. Unfortunately, data for other indications are lacking. Here, we review chemistry, microbiology, pharmacology, efficacy and tolerability of oritavancin.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Kaasch, Achim J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Seifert, HaraldUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-270372
DOI: 10.2217/fmb-2016-0003
Journal or Publication Title: Future Microbiol.
Volume: 11
Number: 7
Page Range: S. 843 - 856
Date: 2016
Publisher: FUTURE MEDICINE LTD
Place of Publication: LONDON
ISSN: 1746-0921
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
ACUTE BACTERIAL SKIN; VANCOMYCIN-RESISTANT ENTEROCOCCI; SINGLE-DOSE ORITAVANCIN; SOFT-TISSUE INFECTIONS; IN-VITRO ACTIVITY; STAPHYLOCOCCUS-AUREUS; PHARMACODYNAMIC EVALUATION; EXPERIMENTAL ENDOCARDITIS; COMPARATOR AGENTS; LY333328Multiple languages
MicrobiologyMultiple languages
Refereed: Yes
URI: http://kups.ub.uni-koeln.de/id/eprint/27037

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item